Q1 2020 EPS Estimates for Charles River Laboratories Intl. Inc (NYSE:CRL) Cut by Analyst

Charles River Laboratories Intl. Inc (NYSE:CRL) – Equities researchers at KeyCorp cut their Q1 2020 earnings estimates for shares of Charles River Laboratories Intl. in a research note issued to investors on Tuesday, February 11th. KeyCorp analyst D. Hooker now anticipates that the medical research company will post earnings of $1.56 per share for the quarter, down from their previous estimate of $1.65. KeyCorp currently has a “Overweight” rating and a $162.00 price objective on the stock. KeyCorp also issued estimates for Charles River Laboratories Intl.’s Q2 2020 earnings at $1.81 EPS, Q3 2020 earnings at $2.04 EPS, Q4 2020 earnings at $2.16 EPS, FY2020 earnings at $7.56 EPS and FY2021 earnings at $8.58 EPS.

A number of other equities analysts have also issued reports on the company. Barclays reaffirmed a “hold” rating and issued a $170.00 target price on shares of Charles River Laboratories Intl. in a research report on Wednesday. Wells Fargo & Co began coverage on Charles River Laboratories Intl. in a research report on Tuesday, January 7th. They issued an “overweight” rating and a $180.00 target price on the stock. Robert W. Baird reaffirmed an “outperform” rating and issued a $185.00 target price (up from $165.00) on shares of Charles River Laboratories Intl. in a research report on Wednesday. Argus reaffirmed a “buy” rating and issued a $170.00 target price on shares of Charles River Laboratories Intl. in a research report on Tuesday, November 19th. Finally, Bank of America lowered Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 target price on the stock. in a research report on Friday, October 18th. Seven investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $169.33.

NYSE CRL opened at $176.48 on Thursday. The stock has a market cap of $7.70 billion, a PE ratio of 37.87, a P/E/G ratio of 1.77 and a beta of 1.18. Charles River Laboratories Intl. has a fifty-two week low of $123.17 and a fifty-two week high of $176.89. The business has a 50 day moving average price of $157.46 and a two-hundred day moving average price of $141.17. The company has a quick ratio of 1.20, a current ratio of 1.43 and a debt-to-equity ratio of 1.30.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $2.01 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.83 by $0.18. The firm had revenue of $691.10 million during the quarter, compared to analysts’ expectations of $685.46 million. Charles River Laboratories Intl. had a return on equity of 21.52% and a net margin of 9.14%. Charles River Laboratories Intl.’s quarterly revenue was up 14.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.49 EPS.

In related news, VP William D. Barbo sold 6,901 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $172.11, for a total transaction of $1,187,731.11. Following the sale, the vice president now directly owns 18,931 shares of the company’s stock, valued at approximately $3,258,214.41. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Birgit Girshick sold 1,051 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $145.55, for a total value of $152,973.05. Following the sale, the vice president now directly owns 18,728 shares in the company, valued at $2,725,860.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,622 shares of company stock worth $3,328,849. 1.80% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its position in shares of Charles River Laboratories Intl. by 1.6% during the 2nd quarter. BlackRock Inc. now owns 4,660,628 shares of the medical research company’s stock valued at $661,344,000 after acquiring an additional 72,827 shares in the last quarter. FMR LLC increased its position in Charles River Laboratories Intl. by 22.7% in the fourth quarter. FMR LLC now owns 1,910,814 shares of the medical research company’s stock worth $291,896,000 after buying an additional 353,231 shares during the period. Kayne Anderson Rudnick Investment Management LLC increased its position in Charles River Laboratories Intl. by 7.8% in the fourth quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,212,910 shares of the medical research company’s stock worth $185,284,000 after buying an additional 87,523 shares during the period. TimesSquare Capital Management LLC increased its position in Charles River Laboratories Intl. by 11.0% in the third quarter. TimesSquare Capital Management LLC now owns 1,007,750 shares of the medical research company’s stock worth $133,396,000 after buying an additional 99,900 shares during the period. Finally, FIL Ltd increased its position in Charles River Laboratories Intl. by 9.0% in the fourth quarter. FIL Ltd now owns 854,234 shares of the medical research company’s stock worth $130,493,000 after buying an additional 70,813 shares during the period. 95.78% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: Holder of Record

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.